Pharmacokinetic considerations for antibody drug conjugates.
about
Challenges and advances in the assessment of the disposition of antibody-drug conjugatesA mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.Site-specific Labeling of a Protein Lysine Residue By Novel Kinetic Labeling Combinatorial Libraries.Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.Tumor endothelial markers as a target in cancer.The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.Strategies to address drug interaction potential for antibody-drug conjugates in clinical development.Strategies for enhanced peptide and protein delivery.Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug ConjugatesAntibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.In vivo biotransformations of antibody-drug conjugates.Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE.Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper.Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates.Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays.Antibody Drug Conjugate bioinformatics: drug delivery through the letterboxFourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.Pharmacokinetics and pharmacodynamics of CD4-anchoring bi-functional fusion inhibitor in monkeys.Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications.Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.Antibody-drug conjugate bioanalysis using LB-LC-MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays.Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.Metal-bound claMP Tag inhibits proteolytic cleavage.Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications.ADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds
P2860
Q28085074-F1F5C344-E2A7-4AFC-9296-23552739330FQ34099745-9FC07A5D-AEBC-4242-A2A8-36F5FD6E1532Q35155487-9859C402-9D16-48FB-8BC6-6261153AB89FQ37566220-3C9D4960-DE32-4F5E-8884-D25066225C2EQ37585671-D7F9849A-7965-4D96-A1C5-D268CC7F8059Q37628646-89E93F5D-A880-4E3A-80B1-D2ABB8508440Q38043525-0FC3A485-B5C5-42D8-912B-7EA204150043Q38092648-FE2557B2-27EB-444C-9FFA-7D3A817D8947Q38103883-0FA19B11-44FD-49E8-A13E-6574F8634EA7Q38104408-33F6769E-5537-41BC-BB34-8DFE83E80F51Q38204975-4310680F-D78F-4D8D-A8ED-A64A508350D6Q38212929-853DC1DD-3A4A-4791-AA5E-7336A054A4C6Q38275051-404196EB-3304-438B-A37F-AE6A0C3C829BQ38453769-D28D3596-2A5D-4A4E-9BEA-DD6BA3A5C04AQ38537257-52CE6517-2452-4F7C-AE0A-CE447397E2D6Q38557525-41BFD018-7B8F-476E-A6E2-D9B323256BEAQ38587550-72CCC816-EDDD-4C24-B9AB-C6DD85A13210Q38618106-F8987F9D-A996-428B-B8DF-11D2CF5D5908Q38669790-A27DAEF8-9CC8-4508-8F97-DDAA52EC4B60Q38817525-F63F7B24-EB88-42F0-A9C3-BF00124347E6Q39090290-AA1378E1-50FD-46CA-A628-01A95DC40A45Q40677785-56F72233-6C16-45AA-98DE-F85A7CBF338DQ41858314-0C7BDD33-29CD-4703-9D17-89FC30F43DDAQ42337744-167087FE-DED9-4F70-81B6-893C34006D22Q43096291-5587F7EF-3FDD-4485-A0D5-F461250788D9Q43175985-F5FAC81F-7C94-4A5D-A774-458289A28031Q43751494-7B338555-4074-4434-9367-08B3DF4C97CAQ45881591-3F9A1221-F54C-4C1F-B75E-0AA867B0A865Q46188788-6C92ABAC-3F14-4580-A8B7-EC610DA62C8DQ46209550-18355A77-A6A3-4000-AA46-F0A498498BD1Q46450170-FE3B64A4-E0C1-4E88-8031-47408E74E991Q46522736-26F541C6-E8FF-474E-8ED3-1A20E3751087Q46535634-DE839268-3C3B-4AA8-A00E-D9DC9BDAA192Q47568807-21F04708-9D21-46CB-92A8-6DF631749EC5Q50624935-88FD6AE5-F3A3-4E52-9B1A-66C25E3CB7C0Q52593621-6B48284A-3E13-4A11-9BCF-A14B6D4F1183Q58869554-D2F2720B-5DB2-4812-B5FF-57159E1A4AED
P2860
Pharmacokinetic considerations for antibody drug conjugates.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacokinetic considerations for antibody drug conjugates.
@en
type
label
Pharmacokinetic considerations for antibody drug conjugates.
@en
prefLabel
Pharmacokinetic considerations for antibody drug conjugates.
@en
P2860
P1476
Pharmacokinetic considerations for antibody drug conjugates.
@en
P2093
Jay Tibbitts
P2860
P304
P356
10.1007/S11095-012-0800-Y
P577
2012-06-28T00:00:00Z